Longer-Term Data Reinforce Safety of Satralizumab in Neuromyelitis Optica Spectrum Disorder
Data from the 2 Phase 3 studies demonstrate satralizumab is well-tolerated in was well-tolerated in neuromyelitis optica spectrum disorder (NMOSD), including adolescents, according to a press release from Genentech.
These data are being presented at the 6th Annual Meeting of the European Academy of Neurology.
“The open-label extension data from the Phase III studies reinforce the safety, observed tolerability and potential of satralizumab as a future treatment option for this chronic condition,” said Professor Jerome de Seze, Department Head of Neurology and Clinical Investigation Centre at the University of Strasbourg, France in the press release. “Although significant strides have been made recently in understanding NMOSD, more approved treatment options offering a well-tolerated safety profile with a less frequent, subcutaneous dosing are needed for this underserved population.”
Read the full press release here.
Related Content
